Heparin monitoring: The confusion continues

被引：11

作者：

Smythe, MA

Koerber, JM

机构：

[1] William Beaumont Hosp, Dept Pharmaceut Serv, Royal Oak, MI 48072 USA

[2] Wayne State Univ, Dept Pharm Practice, Detroit, MI USA

来源：

PHARMACOTHERAPY | 1999年 / 19卷 / 11期

关键词：

D O I：

10.1592/phco.19.16.1240.30881

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：1240 / 1242

页数：3

共 22 条

[1]

ABILDGAARD U, 1990, HAEMOSTASIS, V20, P193

[2] Inability of the activated partial thromboplastin time to predict heparin levels - Time to reassess guidelines for heparin assays [J].

Baker, BA ;

Adelman, MD ;

Smith, PA ;

Osborn, JC .

ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (21) :2475-2479

[3] Problems with monitoring heparin anticoagulation [J].

Bussey, HI .

PHARMACOTHERAPY, 1999, 19 (01) :2-5

[4]

CHIU HM, 1977, BLOOD, V49, P171

[5] Heparin and low-molecular-weight heparin - Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety [J].

Hirsh, J ;

Warkentin, TE ;

Raschke, R ;

Granger, C ;

Ohman, EM ;

Dalen, JE .

CHEST, 1998, 114 (05) :489S-510S

[6]

HOLM HA, 1985, THROMB HAEMOSTASIS, V53, P278

[7]

HOLM HA, 1984, ACTA MED SCAND, V216, P287

[8] CONTINUOUS INTRAVENOUS HEPARIN COMPARED WITH INTERMITTENT SUBCUTANEOUS HEPARIN IN THE INITIAL TREATMENT OF PROXIMAL-VEIN THROMBOSIS [J].

HULL, RD ;

RASKOB, GE ;

HIRSH, J ;

JAY, RM ;

LECLERC, JR ;

GEERTS, WH ;

ROSENBLOOM, D ;

SACKETT, DL ;

ANDERSON, C ;

HARRISON, L ;

GENT, M .

NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (18) :1109-1114

[9] OPTIMAL THERAPEUTIC LEVEL OF HEPARIN-THERAPY IN PATIENTS WITH VENOUS THROMBOSIS [J].

HULL, RD ;

RASKOB, GE ;

ROSENBLOOM, D ;

LEMAIRE, J ;

PINEO, GF ;

BAYLIS, B ;

GINSBERG, JS ;

PANJU, AA ;

BRILLEDWARDS, P ;

BRANT, R .

ARCHIVES OF INTERNAL MEDICINE, 1992, 152 (08) :1589-1595

[10] Antithrombotic therapy for venous thromboembolic disease [J].

Hyers, TM ;

Agnelli, G ;

Hull, RD ;

Weg, JG ;

Morris, TA ;

Samama, M ;

Tapson, V .

CHEST, 1998, 114 (05) :561S-578S

← 1 2 3 →